

Abierto el plazo para la presentación de propuestas a la convocatoria "**JTI-IMI 2: Innovative Medicines Initiative 2 2017- Research and Innovation Action (RIA) & Coordination and Support Action (CSA)**".

**Objeto:**

La Iniciativa sobre Medicamentos Innovadores 2 (IMI 2) se basará en los éxitos obtenidos bajo la anterior iniciativa IMI-1 y reunirá empresas, universidades, laboratorios públicos, grupos de pacientes y PYMEs para encontrar vacunas, medicamentos y tratamientos que hagan frente a los desafíos crecientes de la salud de Europa y asegure el futuro de la competitividad internacional de la industria farmacéutica europea.

**Datos de la convocatoria:**

Entidad Financiadora: COMISION EUROPEA

Fecha de Publicación : 30/11/2017

Dirección web :

<https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2017-13-two-stage.html>

Plazo de Presentación de Solicitudes:

**Del 30/11/2017 al 28/02/2018**

**Características:**

Apertura de la Convocatoria 13:

Identificador Convocatoria: H2020-JTI-IMI2-2017-13-two-stage

Tipos de acción: Research and Innovation Action (RIA) & Coordination and Support Action (CSA)

Publicación: 30 de noviembre de 2017

Cierre 1ª etapa: 28 de febrero de 2018 (17:00:00)

Cierre 2ª etapa: 6 de septiembre de 2018 (17:00:00)

Presupuesto: IMI2 JU = 116,421 M€ financiación pública (+ EFPIA y Socios IMI2 JU = 106,629 M€)

Topics:

Topic 1: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches (RIA);



- Topic 2: Genome-Environment Interaction in Inflammatory Skin Disease (RIA);
- Topic 3: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use (RIA);
- Topic 4: Mitochondrial Dysfunction in Neurodegeneration (RIA);
- Topic 5: Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative (CSA);
- Topic 6: A sustainable European induced pluripotent stem cell platform (RIA);
- Topic 7: Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice (DIAMOND) (RIA);
- Topic 8: Human Tumour Microenvironment Immunoprofiling (RIA);
- Topic 9: ConcePTION - Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology & Breastfeeding to Improve Outcomes Now (RIA);
- Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system (RIA);
- Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease (RIA);
- Topic 12: Pilot Programme on a Clinical Compound for Repurposing- Cardiovascular diseases and diabetes (RIA);
- Topic 13: Pilot Programme on a Clinical Compound for Repurposing - Respiratory diseases (RIA);
- Topic 14: Pilot Programme on a Clinical Compound for Repurposing - Neurodegenerative diseases (RIA);
- Topic 15: Pilot Programme on a Clinical Compound for Repurposing - Rare/orphan diseases (RIA).

Si eres PDI de la UC3M accede al [portal del investigador](#) para obtener más información.